To include your compound in the COVID-19 Resource Center, submit it here.

New Products to Watch

New Products to Watch

Selected drugs that received regulatory approval in 2009.

Company Product Indication 2009 approval
Allergan Inc. (NYSE:AGN) Ozurdex dexamethasone Macular edema U.S.
Allos Therapeutics Inc. (NASDAQ:ALTH) Folotyn pralatrexate Relapsed or refractory peripheral T cell lymphoma (PTCL) U.S.
AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Feraheme ferumoxytol Iron deficiency anemia U.S.
Amgen Inc. (NASDAQ:AMGN) Nplate romiplostim Chronic idiopathic thrombocytopenic purpura (ITP) EU
AstraZeneca plc (LSE:AZN; NYSE:AZN)/Bristol-Myers Squibb Co. (NYSE:BMY) Onglyza saxagliptin Type II diabetes U.S./EU
Baxter International Inc. (NYSE:BAX)

Read the full 1033 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers